Personal genome services provide consumer genomics, in the area of genomics that deals with the sequencing, analysis, and interpretation of an individual's genome. Single-nucleotide polymorphism analysis chips, and partial or whole-genome sequencing, are used at the genotyping step. Once the genotypes have been determined, the individual's variants may be compared to existing literature to assess the likelihood of trait expression, ancestry inference, and illness risk.This growth is primarily driven by Rising Number of Government Genome Projects and New Products and Innovative Service to Favor the Adoption of Sequencing.
Globally, a noticeable market trend is evident Technological Advancement in Polymerase Chain Reaction (PCR) and Next-Generation Sequencing Microarray (NGS). Major Players, such as Illumina, Inc. (United States), 23andMe (United States), Veritas Genetics (United States), Thermo Fisher Scientific (United States), Nebula Genomics (United States), 10x Genomics (United States), Agilent Technologies (United States), Invitae Corporation (United States), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (United States) and F. Hoffmann-La Roche Ltd. (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
On 17 Sep 2020, QIAGEN N.V. announced the acquisition of NeuMoDx Molecular, Inc. to enhance its strong position in automated molecular testing. NeuMoDx automation solutions based on PCR testing technology for medium and high throughput will now be included in QIAGEN's offering. QIAGEN will be willing to deliver laboratory demands in nearly any environment for molecular diagnostics owing to the NeuMoDx systems' complete integration. Both firms are expanding our product line and global distribution.
On 06 Jan 2021, Illumina and Helix announced the collaboration to improve the United States' national surveillance infrastructure in order to track the development and spread of new SARS-CoV-2 strains. The country's existing surveillance efforts to discover and characterize new variants of SARS-CoV-2 will be considerably expanded thanks to Illumina's sequencing technology and experience, as well as Helix's nationwide COVID-19 testing footprint.
- Rising Number of Government Genome Projects
- New Products and Innovative Service to Favor the Adoption of Sequencing
- Technological Advancement in Polymerase Chain Reaction (PCR) and Next-Generation Sequencing Microarray (NGS)
- High-Cost Implementation Associated with Personal Genome Service
Growth in the Personalized Medicine Market and Advancements of Gene Therapy Replacing Traditional Drugs and Surgeries
Lack of Trained Technicians in Developing Countries
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Personal Genome Services Study Sheds Light on
The Personal Genome Services Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Personal Genome Services industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Personal Genome Services industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Personal Genome Services Market?
The Personal Genome Services market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Personal Genome Services Market?
Top performing companies in the Global Personal Genome Services market are Illumina, Inc. (United States), 23andMe (United States), Veritas Genetics (United States), Thermo Fisher Scientific (United States), Nebula Genomics (United States), 10x Genomics (United States), Agilent Technologies (United States), Invitae Corporation (United States), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (United States) and F. Hoffmann-La Roche Ltd. (Switzerland), to name a few.
3. Which region dominated the worldwide market for Personal Genome Services in 2020?
is dominating the Personal Genome Services Market.